Core Viewpoint - Watson Bio's subsidiary has applied for clinical trials of a freeze-dried mRNA vaccine for herpes zoster, which has been accepted by the National Medical Products Administration [1] Company Summary - The mRNA vaccine is developed in collaboration with Blue Magpie Bio and Fudan University, utilizing an independently developed mRNA vaccine technology platform [1] - Currently, there are no mRNA-based herpes zoster vaccines available on the market, with existing options being live attenuated and recombinant vaccines [1] - The acceptance of the clinical trial application will not have a significant impact on the company's operating performance for the current year [1] Industry Summary - The development of mRNA vaccines represents a new technological approach in the vaccine industry, particularly for diseases like herpes zoster [1] - The absence of mRNA-based herpes zoster vaccines in the global market indicates a potential opportunity for innovation and market entry [1]

人民财讯9月19日电，沃森生物(300142)9月19日公告，公司子公司北京沃森创新生物技术有限公司、云 南疫苗实验室有限公司、玉溪沃森生物技术有限公司联合复旦大学、上海蓝鹊生物医药有限公司联合研 发的冻干带状疱疹病毒mRNA疫苗向国家药品监督管理局申请临床试验，并于近日获得受理通知书。 转自：证券时报 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 由云南沃森生物技术股份有限公司（以下简称"公司"或"沃森生物"）子 公司北京沃森创新生物技术有限公司、云南疫苗实验室有限公司、玉溪沃森生物 技术有限公司联合复旦大学、上海蓝鹊生物医药有限公司（以下简称"蓝鹊生 物"）联合研发的冻干带状疱疹病毒mRNA疫苗（以下简称"本疫苗"）向国家 药品监督管理局申请临床试验，并于近日获得《受理通知书》。其主要内容如下： 证券代码：300142 证券简称：沃森生物 公告编号：2025-052 云南沃森生物技术股份有限公司 关于冻干带状疱疹病毒 mRNA 疫苗临床试验申请获得受理的公告 受理结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 本疫苗为沃森生物联合蓝鹊生物、复旦大学共同基于自主研发建立的"mRNA 疫苗技术平台"开发，接种本疫苗后，可刺激机体产生抗带状疱疹病毒的免疫力， 用于预防带状疱疹。 目前全球已上市的带状疱疹疫苗主要为减毒活疫苗和重组疫苗，包括默沙东 Zostavax（减毒活疫苗）、SK生物科学SkyZoster（减毒活疫苗）、百克 ...

云南沃森生物技术股份有限公司 证券代码：300142 证券简称：沃森生物 公告编号：2025-053 关于全资子公司完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 经云南沃森生物技术股份有限公司（以下简称"公司"）2025 年度总裁办公 会第二十六次会议审议通过，根据全资子公司北京沃森创新生物技术有限公司（以 下简称"北京沃森"）业务发展的需要，同意公司对北京沃森增资 4.4 亿元。本次 增资的目的是保障北京沃森日常运营的资金需求，公司将按北京沃森的实际需求 对其分次实缴注册资本。本次增资完成后，公司仍然持有北京沃森 100%股权。 北京沃森已于日前办理完成本次增资的工商变更登记手续并取得了工商行政 管理部门换发的《营业执照》，其主要信息如下： 名称：北京沃森创新生物技术有限公司 统一社会信用代码：91110115MA01QW4U8G 类型：有限责任公司（法人独资） 法定代表人：董少忠 注册资本：110,000万元 成立日期：2020年4月21日 住所：北京市大兴区中关村科技园区大兴生物医药产业基地永大路38号1幢4 层409-10室 ...

Group 1 - The core point of the article is that Watson Bio's subsidiary has had its clinical trial application for a freeze-dried herpes zoster virus mRNA vaccine accepted [1] Group 2 - The acceptance of the clinical trial application indicates progress in the development of innovative vaccine technology within the company [1] - This development could potentially enhance the company's position in the biopharmaceutical industry, particularly in the vaccine segment [1] - The mRNA vaccine technology is gaining traction globally, which may lead to increased interest and investment in similar projects [1]

Company Overview - Watson Bio, established on January 16, 2001, and listed on November 12, 2010, is located in Kunming, Yunnan Province. The company specializes in the research, production, and sales of vaccine products [1] - The main revenue composition includes self-developed vaccine products (94.82%), intermediate products (4.67%), other (supplement) (0.26%), and technical services (0.24%) [1] Financial Performance - For the first half of 2025, Watson Bio reported a revenue of 1.154 billion yuan, a year-on-year decrease of 19.47%. The net profit attributable to shareholders was 43.16 million yuan, down 74.69% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 403 million yuan, with 47.98 million yuan distributed over the past three years [3] Stock Performance - As of September 19, Watson Bio's stock price was 11.95 yuan per share, with a market capitalization of 19.112 billion yuan. The stock has decreased by 0.99% year-to-date and by 3.94% over the last five trading days [1] - The stock experienced a net outflow of 37.44 million yuan in principal funds, with significant selling pressure observed [1] Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 117,300, while the average circulating shares per person decreased by 3.88% to 13,268 shares [2] - The largest circulating shareholder is E Fund's ChiNext ETF, holding 40.27 million shares, a decrease of 1.0618 million shares from the previous period [3]

Group 1 - The company has launched two pneumococcal vaccines: a 13-valent pneumococcal polysaccharide conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine [2] - The company is currently conducting clinical research on a 20-valent pneumococcal polysaccharide conjugate vaccine, which received the Drug Clinical Trial Approval Notification in April 2025 and is preparing for Phase I clinical research [2]

证券日报网讯沃森生物（300142）9月16日在互动平台回答投资者提问时表示，关于公司研发投入的相 关情况请具体查阅公司已披露的历次定期报告相关内容，并以定期报告的数据为准。 ...

证券日报网讯沃森生物（300142）9月16日在互动平台回答投资者提问时表示，目前，公司共有8个自主 疫苗产品(14个品规)正式上市销售，包括：13价肺炎结合疫苗(西林瓶型和预灌封型)、双价HPV疫苗(西 林瓶型和预灌封型)、23价肺炎多糖疫苗(西林瓶型和预灌封型)、b型流感嗜血杆菌结合疫苗(西林瓶型和 预灌封型)、A群C群脑膜炎球菌多糖结合疫苗(西林瓶型和预灌封型)、ACYW135群脑膜炎球菌多糖疫苗 (西林瓶型和预灌封型)、A群C群脑膜炎球菌多糖疫苗(西林瓶型)和吸附无细胞百白破联合疫苗(西林瓶 型)。上述疫苗产品主要用于预防由特定病原微生物感染所引起的相关疾病。公司20价肺炎球菌多糖结 合疫苗于2025年4月获得《药物临床试验批准通知书》，正在开展Ⅰ期临床研究的准备工作。公司在研 疫苗产品的研发若有实质性和阶段性进展公司会及时披露，后续进展情况请关注公司披露的相关信息。 ...

Core Viewpoint - The vaccine industry is experiencing a downturn, with significant revenue and profit declines among major companies, attributed to price wars, vaccine hesitancy, and intense competition [4][5][10][20]. Group 1: Industry Performance - In the first half of 2025, the overall vaccine revenue of listed companies in China decreased by 60% year-on-year, and net profit dropped by 113% [5]. - Major vaccine companies like Zhifei Biological and Wantai Biological reported their first half-year losses since going public, with net profits declining by 127% and 155% respectively [5][10]. - Only six out of 17 listed vaccine companies achieved profitability, with the highest profit being 122 million yuan from Chengda Biological [5]. Group 2: Price Wars - The price of flu vaccines has significantly dropped, with some prices reaching as low as 5.5 yuan per dose, leading to a continuous price war in the market [8][9]. - Wantai Biological's revenue from its main product, the bivalent HPV vaccine, fell by 38% to 844 million yuan, marking its first loss since listing [10]. - The price competition has also affected other vaccines, including HPV and shingles vaccines, with prices dropping dramatically in recent years [9][10][11]. Group 3: Vaccine Hesitancy - Vaccine hesitancy has become a significant issue, particularly for non-mandatory vaccines like HPV and flu vaccines, with many individuals expressing doubts about their effectiveness [13][14][15]. - The average flu vaccine coverage in China remains below 4%, significantly lower than in developed countries where it is around 50% [15]. - Factors contributing to vaccine hesitancy include dissatisfaction with COVID-19 vaccine outcomes, misinformation, and a lack of awareness regarding adult vaccinations [15][16]. Group 4: Future Outlook - Experts predict that the current downturn in the vaccine industry may last for five to ten years, with potential consolidation and elimination of weaker companies [20]. - The industry faces challenges in changing public perception and increasing adult vaccination rates, which are crucial for market expansion [20]. - The competition is expected to remain fierce, with many companies struggling to differentiate their products in a saturated market [19][20].